Alimera Sciences, Inc. (ALIM)
USD 5.54
(-0.18%)
USD 5.54
(-0.18%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 80.75 Million USD | 49.19% |
| 2022 | 54.12 Million USD | -8.3% |
| 2021 | 59.02 Million USD | 16.15% |
| 2020 | 50.82 Million USD | -5.79% |
| 2019 | 53.94 Million USD | 14.85% |
| 2018 | 46.97 Million USD | 30.79% |
| 2017 | 35.91 Million USD | 4.6% |
| 2016 | 34.33 Million USD | 53.01% |
| 2015 | 22.43 Million USD | 166.39% |
| 2014 | 8.42 Million USD | 349.95% |
| 2013 | 1.87 Million USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 23.01 Million USD | -12.53% |
| 2024 Q2 | 27 Million USD | 17.34% |
| 2023 Q4 | 26.3 Million USD | 12.59% |
| 2023 Q3 | 23.36 Million USD | 33.22% |
| 2023 FY | 80.75 Million USD | 49.19% |
| 2023 Q1 | 13.54 Million USD | -3.44% |
| 2023 Q2 | 17.53 Million USD | 29.47% |
| 2022 Q2 | 14.6 Million USD | 22.74% |
| 2022 Q4 | 14.02 Million USD | 3.17% |
| 2022 Q1 | 11.89 Million USD | -14.76% |
| 2022 Q3 | 13.59 Million USD | -6.89% |
| 2022 FY | 54.12 Million USD | -8.3% |
| 2021 Q4 | 13.95 Million USD | 14.86% |
| 2021 Q2 | 21.7 Million USD | 93.53% |
| 2021 Q1 | 11.21 Million USD | -18.59% |
| 2021 FY | 59.02 Million USD | 16.15% |
| 2021 Q3 | 12.15 Million USD | -44.0% |
| 2020 Q1 | 14.53 Million USD | -16.22% |
| 2020 Q2 | 10.03 Million USD | -30.94% |
| 2020 Q3 | 12.47 Million USD | 24.26% |
| 2020 Q4 | 13.77 Million USD | 10.43% |
| 2020 FY | 50.82 Million USD | -5.79% |
| 2019 Q2 | 10.85 Million USD | -15.79% |
| 2019 Q1 | 12.89 Million USD | -14.71% |
| 2019 Q4 | 17.34 Million USD | 35.0% |
| 2019 FY | 53.94 Million USD | 14.85% |
| 2019 Q3 | 12.85 Million USD | 18.38% |
| 2018 Q3 | 11.13 Million USD | 2.02% |
| 2018 FY | 46.97 Million USD | 30.79% |
| 2018 Q1 | 9.8 Million USD | 7.22% |
| 2018 Q2 | 10.91 Million USD | 11.38% |
| 2018 Q4 | 15.11 Million USD | 35.71% |
| 2017 FY | 35.91 Million USD | 4.6% |
| 2017 Q4 | 9.14 Million USD | -6.56% |
| 2017 Q3 | 9.78 Million USD | -5.63% |
| 2017 Q2 | 10.36 Million USD | 56.66% |
| 2017 Q1 | 6.61 Million USD | -38.02% |
| 2016 Q4 | 10.67 Million USD | 28.67% |
| 2016 FY | 34.33 Million USD | 53.01% |
| 2016 Q1 | 5.8 Million USD | -0.38% |
| 2016 Q3 | 8.29 Million USD | -13.17% |
| 2016 Q2 | 9.55 Million USD | 64.75% |
| 2015 Q4 | 5.82 Million USD | -15.62% |
| 2015 FY | 22.43 Million USD | 166.39% |
| 2015 Q1 | 3.93 Million USD | 126.19% |
| 2015 Q2 | 5.77 Million USD | 46.67% |
| 2015 Q3 | 6.9 Million USD | 19.48% |
| 2014 Q2 | 2.19 Million USD | 5.09% |
| 2014 Q4 | 1.74 Million USD | -27.7% |
| 2014 Q3 | 2.4 Million USD | 9.95% |
| 2014 Q1 | 2.08 Million USD | 122.89% |
| 2014 FY | 8.42 Million USD | 349.95% |
| 2013 FY | 1.87 Million USD | 0.0% |
| 2013 Q2 | 179 Thousand USD | 0.0% |
| 2013 Q3 | 758 Thousand USD | 323.46% |
| 2013 Q4 | 935 Thousand USD | 23.35% |
| 2013 Q1 | - USD | -100.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | 5000.00 USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | -100.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q4 | 73 Thousand USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 83.412% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -59.647% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 85.752% |
| Cosmos Health Inc. | 53.37 Million USD | -51.29% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -7402.195% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 30.584% |
| Cronos Group Inc. | 88.84 Million USD | 9.103% |
| Incannex Healthcare Limited | 12 Thousand USD | -672850.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 37.039% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -235.179% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -235.179% |
| SCYNEXIS, Inc. | 140.14 Million USD | 42.377% |
| Safety Shot Inc | 202.67 Thousand USD | -39745.068% |
| Theratechnologies Inc. | 81.76 Million USD | 1.235% |
| Alpha Teknova, Inc. | 36.68 Million USD | -120.134% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -149.945% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 88.036% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -534.111% |
| Dynavax Technologies Corporation | 232.28 Million USD | 65.235% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 81.76% |
| Radius Health, Inc. | 2.88 Billion USD | 97.198% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -4087.406% |
| Alvotech | 91.43 Million USD | 11.681% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 82.61% |
| SIGA Technologies, Inc. | 139.91 Million USD | 42.284% |
| Shineco, Inc. | 9.8 Million USD | -723.864% |
| Silver Spike Investment Corp. | 11.72 Million USD | -588.902% |
| Journey Medical Corporation | 79.18 Million USD | -1.987% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -1286.957% |
| Embecta Corp. | 1.12 Billion USD | 92.795% |
| Harrow Health, Inc. | 130.19 Million USD | 37.974% |
| Procaps Group, S.A. | 409.92 Million USD | 80.3% |
| Biofrontera Inc. | 34.07 Million USD | -137.017% |
| DURECT Corporation | 8.54 Million USD | -844.712% |
| PainReform Ltd. | - USD | -Infinity% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 86.708% |
| OptiNose, Inc. | 70.98 Million USD | -13.759% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -1139.857% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 81.356% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -104.169% |
| ProPhase Labs, Inc. | 44.38 Million USD | -81.944% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 92.065% |
| Procaps Group S.A. | 409.92 Million USD | 80.3% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -6102.304% |
| Viatris Inc. | 15.42 Billion USD | 99.477% |
| Rockwell Medical, Inc. | 83.61 Million USD | 3.418% |
| Aytu BioPharma, Inc. | 81 Million USD | 0.306% |
| Tilray Brands, Inc. | 788.94 Million USD | 89.764% |
| PetIQ, Inc. | 1.1 Billion USD | 92.672% |
| Talphera, Inc. | 651 Thousand USD | -12304.608% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 95.721% |
| Assertio Holdings, Inc. | 152.06 Million USD | 46.896% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -188.789% |
| Hempacco Co., Inc. | 4.04 Million USD | -1896.076% |
| Alvotech | 91.43 Million USD | 11.681% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 93.771% |
| Kamada Ltd. | 144.75 Million USD | 44.215% |
| Currenc Group, Inc. | 53.25 Million USD | -51.635% |
| Indivior PLC | 1.09 Billion USD | 92.612% |
| Evoke Pharma, Inc. | 5.18 Million USD | -1458.768% |
| Flora Growth Corp. | 76.07 Million USD | -6.156% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -7402.195% |
| Evolus, Inc. | 202.08 Million USD | 60.04% |
| HUTCHMED (China) Limited | 837.99 Million USD | 90.363% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 87.468% |
| Akanda Corp. | 2.16 Million USD | -3638.521% |